J&J, Legend's Carvykti bid for earlier multiple myeloma use will face FDA adcomm
Fierce Pharma
JANUARY 23, 2024
Early evidence showing Carvykti’s potential to prolong patients’ lives in an earlier multiple myeloma setting didn’t save Johnson & Johnson and Legend Biotech’s CAR-T medicine from a public int | Early evidence showing the drug's potential to prolong patients' lives didn't save Johnson & Johnson and Legend Biotech's Carvykti from a public interrogation by the FDA.
Let's personalize your content